Headquartered in Miami, FL·Fiscal year ends December·NASDAQ: SMMT·smmttx.com
About Summit Therapeutics
Summit Therapeutics Inc. is a clinical-stage biopharmaceutical oncology company with no product revenue. Its business centers on ivonescimab (SMT112), an investigational bispecific antibody that combines PD-1 immune checkpoint blockade with VEGF anti-angiogenesis in a single tetravalent molecule. Summit in-licensed ivonescimab from Akeso Inc. in January 2023. It holds exclusive development and commercialization rights in North America, South America, Europe, the Middle East, Africa and Japan; Akeso retains rights elsewhere, including China, where the drug has been approved since May 2024. Summit sponsors five global Phase III studies: HARMONi, HARMONi-3 and HARMONi-7 in NSCLC, HARMONi-GI3 in colorectal cancer, and HARMONi-GU1 in bladder cancer. It also runs a Phase II study in clear cell renal cell carcinoma and supports cooperative-group Phase III studies in head and neck cancer (ILLUMINE) and biliary tract cancer (EA2251). A BLA for ivonescimab plus chemotherapy in EGFR-mutated non-squamous NSCLC has a PDUFA date of November 14, 2026. Summit pursues combination collaborations with AstraZeneca, Daiichi Sankyo, GSK, Revolution Medicines and Arcus Biosciences, and supports more than 65 investigator-sponsored trials. In October 2026, AstraZeneca completed a $2.0 billion strategic equity investment in the company. Summit funds operations through equity, including an at-the-market offering program. Updated
AstraZeneca just locked in a price to own 12% of Summit Therapeutics that the open market refuses to match, and two clinical deadlines in 2026 will determine whether Wall Street or the…
After years of lagging the market, healthcare may be taking on a new role in investor portfolios. Speaking on CNBC, Mizuho healthcare strategist Jared Holz reframed the sector, arguing that years of…
Clinical-stage biotech is one of the few corners of the market where a sub-$30 share price genuinely matters: small-cap oncology names can re-rate violently around a single Phase 3 readout or FDA…
Insider buys can be a telltale sign of a turnaround, as these investments give you a window into where management stands with a company. Studies have shown that insider buys often lead…
In the past week or so, a gold and silver miner, an offshore driller, and a biotech saw some huge insider buying. These were not the only notable purchases.
The highlight of recent insider buying is an enormous purchase of Tesla shares by CEO Elon Musk. But it wasn't the only notable buy in the past week or so.
Insiders know their company the best. So, if they’re buying a good deal of shares, there’s often a reason for it. However, don’t buy a stock just because an insider is buying. …
Summit Therapeutics Inc. is a clinical-stage biopharmaceutical oncology company with no product revenue. Its business centers on ivonescimab (SMT112), an investigational bispecific antibody that combines PD-1 immune checkpoint blockade with VEGF anti-angiogenesis in a single tetravalent molecule.